Overview

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Status:
Completed

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer therapy, are PARP inhibitor naïve, and have platinum-resistant but not refractory disease. This study is a sub study of the master protocol - OPAL (NCT03574779).

Phase:

Phase 2

Details

Lead Sponsor:

Tesaro, Inc.

Treatments:

Bevacizumab
Niraparib